

Weekly New Drug Approvals

Apr. 1st 2024

1. Sotatercept

FDA Approval Date: Mar. 26th, 2024

Brand name: Winrevair

Indication: Pulmonary Arterial Hypertension

Mechanism: ACVR2A modulators/
activin receptor antagonists

Dosage form: Injection

Company: Merck Sharp & Dohme



Sotatercept: A soluble fusion protein composed of the extracellular domain of the activin receptor type IIA (ActRIIA) linked to the Fc portion of human IgG1 with anabolic bone activity.



2. Zolbetuximab

PMDA Approval Date: Mar. 26th, 2024

Brand name: VYLOY

Indication: CLDN18.2 positive Stomach Cancer

Mechanism: CLDN18.2 inhibitors

Dosage form: Injection

Company: Astellas Pharma

Zolbetuximab is an investigational, first-in-class chimeric IgG1 monoclonal antibody (mAb) that targets and binds to claudin 18.2 (CLDN18.2), a transmembrane protein. Zolbetuximab acts by binding to CLDN18.2 on the cancer cell surface of gastric epithelial cells.